Our data suggest that this results from a switch from sulfonylureas to DPP-4 inhibitors in patients with CKD <60 mL/min/1.73 m2, as we observed that DPP-4 inhibitor prescriptions are the highest for GFR between 30 and 60 mL/min/1.73 m2. The gene discussed is DPP4; the disease is chronic kidney disease.